Unknown

Dataset Information

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.


ABSTRACT:

Lessons learned

The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its first stage for poor activity.

Background

Androgen receptors (AR) are expressed in most breast cancers, and AR-agonists have some activity in these neoplasms. We

SUBMITTER: Pietri E 

PROVIDER: S-EPMC6656524 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature